RecruitingNot ApplicableNCT06751199

UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes

Investigation of Dose Escalation and Dose Expansion Study on the Safety and Efficacy of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes

Sponsor

Shanghai Changzheng Hospital

Enrollment

16 participants

Start Date

Dec 30, 2024

Study Type

INTERVENTIONAL

Conditions

Diabetes

Summary

The aim is to Investigate the safety and efficacy of Portal vein infusion Allogeneic Human umbilical cord mesenchymal stem cells combined with Allogeneic islet transplantation for the treatment of diabetes

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called allogeneic islet and a drug called human umbilical cord mesenchymal stem cells for people with diabetes. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGhuman umbilical cord mesenchymal stem cells

Portal vein infusion human umbilical cord mesenchymal stem cells

DRUGallogeneic islet

Portal vein infusion of allogeneic islet

Locations(1)

Shanghai Changzheng Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06751199

Related Trials

Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma

NCT055615951 location

Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes

NCT056431441 location